These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 19427610)
1. Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery? Rosencher N; Bellamy L; Arnaout L Arch Cardiovasc Dis; 2009 Apr; 102(4):327-33. PubMed ID: 19427610 [TBL] [Abstract][Full Text] [Related]
2. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Eriksson BI; Quinlan DJ Drugs; 2006; 66(11):1411-29. PubMed ID: 16906775 [TBL] [Abstract][Full Text] [Related]
3. Dabigatran: new drug. Continue to use heparin, a better-known option. Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411 [TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY; Larsen TB; Skjøth F; Rasmussen LH J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324 [TBL] [Abstract][Full Text] [Related]
5. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P; Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130 [TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Borris LC Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250 [TBL] [Abstract][Full Text] [Related]
7. [Rivaroxaban: mode of action]. Drouet L Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786 [TBL] [Abstract][Full Text] [Related]
8. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience. Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358 [TBL] [Abstract][Full Text] [Related]
9. New oral anticoagulants: will they replace warfarin? Little JW Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 May; 113(5):575-80. PubMed ID: 22668618 [TBL] [Abstract][Full Text] [Related]
10. A new generation of oral direct anticoagulants. Soff GA Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):569-74. PubMed ID: 22345595 [TBL] [Abstract][Full Text] [Related]
11. [Rivaroxaban (Xarelto): efficacy and safety]. Rosencher N; Arnaout L; Chabbouh T; Bellamy L Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784 [TBL] [Abstract][Full Text] [Related]
12. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques]. Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM; Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209 [TBL] [Abstract][Full Text] [Related]
13. Novel oral anticoagulants--key messages for the angiologist. Haas S; Spannagl M; Schellong SM Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619 [TBL] [Abstract][Full Text] [Related]
14. [New clinical perspectives in the management of oral direct anticoagulant agents]. Marco P; Zamorano JL; Chana F; Llau JV Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969 [No Abstract] [Full Text] [Related]
15. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. Blann AD Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993 [TBL] [Abstract][Full Text] [Related]
16. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S; Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867 [TBL] [Abstract][Full Text] [Related]
17. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P; Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766 [TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516 [TBL] [Abstract][Full Text] [Related]
19. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. Baglin T Br J Haematol; 2013 Oct; 163(2):160-7. PubMed ID: 23937286 [TBL] [Abstract][Full Text] [Related]
20. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Huisman MV; Quinlan DJ; Dahl OE; Schulman S Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]